The effects of Skekar Tighal on covid-19

Not Applicable

• Conditions: Covid-19.; Pneumonia due to SARS-associated coronavirus; J12.81

• Registration Number: IRCT20211029052904N1
• Lead Sponsor: Artesh University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 January 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Age between 18-65
Written informed consent
Covid-19 patients (PCR positive test or clinical symptoms such as fever > 38, respiratory rate = 24, dry cough, myalgia, asthenia, anosmia, and or anorexia
Admission to general corvid-19 unit in hospital
Patients who estimate that reside in hospital at least 7 days.
Non ICU patients

Exclusion Criteria

Did not write informed consent
Pregnancy and lactation
Smoking
Usage of other herbal medicine
Hypertension (definition by ACC/AHA SBP/DBP = 130/80)

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
C reactive protein. Timepoint: At baseline (day 0) and end of the study (day 8). Method of measurement: ELISA commercial diagnostic kit.;Assess the severity of cough. Timepoint: At baseline (day 0) and end of the study (day 8). Method of measurement: Visual Analogue Scale.;Alanine transaminase. Timepoint: At baseline (day 0) and end of the study (day 8). Method of measurement: Spectrophotometry.;Aspartate transaminase. Timepoint: At baseline (day 0) and end of the study (day 8). Method of measurement: Spectrophotometry.

Secondary Outcome Measures

Name	Time	Method
Hospitalization days. Timepoint: Continuous. Method of measurement: Discharge day minus first day.